About The NovaSure Endometrial Ablation Procedure

NovaSure endometrial ablation is a unique, radiofrequency impedance-based technology, which delivers a customized treatment to lighten or end your patients' heavy menstrual bleeding. The NovaSure endometrial ablation procedure has the fastest treatment time, requires no hormonal pretreatment, and can be performed at any time during a woman's menstrual cycle - in the hospital or in your office.

The NovaSure endometrial ablation procedure is safe and comfortable in either the operating room or the office setting. Unique radiofrequency impedance-based technology delivers customized, proven patient results.

Proven Outcomes
After 14 years of treating AUB with minimally invasive, safe, non-hormonal treatment, the NovaSure endometrial ablation procedure has time tested and durable results. The proven high rate of success, amenorrhea and patient satisfaction are not only a testament to the 2 million women treated but also are confirmed through long-standing, extensive, prospective clinical data.
The below data is representative of:
• Over 700 subjects
• 10 peer-reviewed publications
• A proven record of safety and efficacy

*1-year rates based on intent-to-treat population.        **1-year rates based on an evaluable.

METHODOLOGY: Ten prospective studies, six single-arm NovaSure trials and four randomized controlled trials were reviewed for amenorrhea rate, success rate and patient satisfaction. The follow-up period for these measures was 12 months. Studies were chosen based on similar protocols and endpoints. (See aggregate data below)

Novasure Procedure - 10 year Review

Please click here to view 10 year's of data for the NovaSure procedure.

Advanced Technology

Impedance-based technology customizes patient results

The NovaSure endometrial ablation system:

  • Offers a consistent depth of ablation, regardless of endometrial thickness, customized to uterine cavity size
  • Has a proactive safety check prior to procedure to assess cavity integrity
  • Requires no pretreatment and is not cycle dependent
Safety and Comfort

A safe, comfortable procedure in either the OR or office setting

  • Average 90-second treatment time
  • No uterine distention
  • 73% of patients in the pivotal trial received IV or local sedation1

Post-procedural pain and cramping rates:

  • 97% of patients experienced no procedural pain at less than 24 hours2
  • 99% of patients experienced no procedural pain from 24 hours to 2 weeks2
Steps of the Procedure


Indications and Contraindications

NovaSure System Indications:
The NovaSure system is intended to ablate the endometrial lining of the uterus in pre-menopausal women with menorrhagia (heavy bleeding) due to benign causes for whom childbearing is complete.

NovaSure System Contraindications:
The NovaSure impedance controlled endometrial ablation system is contraindicated for use in:

  • A patient who is pregnant or who wants to become pregnant in the future. Pregnancies following ablation can be dangerous for both mother and fetus.
  • A patient with known or suspected endometrial carcinoma (uterine cancer) or pre-malignant conditions of the endometrium, such as unresolved adenomatous hyperplasia.
  • A patient with any anatomic condition (e.g., history of previous classical cesarean section or transmural myomectomy) or pathologic condition (e.g., long-term medical therapy) that could lead to weakening of the myometrium.
  • A patient with active genital or urinary tract infection at the time of the procedure (e.g., cervicitis, vaginitis, endometritissalpingitis, or cystitis).
  • A patient with a intrauterine device (IUD) currently in place.
  • A patient with a uterine cavity length less than 4 cm. The minimum length of the electrode array is 4 cm. Treatment of a uterine cavity with a length less than 4 cm will result in thermal injury to the endocervical canal.
  • A patient with a uterine cavity width less than 2.5 cm, as determined by the WIDTH dial of the disposable device following device deployment.
  • A patient with active pelvic inflammatory disease.
  1. Cooper J, Gimpelson R, Laberge P et al. A randomized, multicenter trial of safety and efficacy of the Novasure System in the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002;9:418-428
  2. NovaSure Instructions for Use.
NovaSure Aggregate Data - Bibliography
NovaSure Aggregate Data - Bibliography
  • Cooper J, Gimpelson R, Laberge P, Galen D, Garza-Leal JG, Scott J, Leyland N, Martyn P, Liu J. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002 Nov;9(4):418-28.
  • Gallinat A, Nugent W. NovaSure impedance-controlled system for endometrial ablation. J Am Assoc Gynecol Laparosc. 2002 Aug;9(3):283-9.
  • Busund B, Erno LE, Grønmark A, Istre O. Endometrial ablation with NovaSure GEA, a pilot study. Acta Obstet Gynecol Scand. 2003 Jan;82(1):65-8.
  • Fulop T, Rákóczi I, Barna I. NovaSure impedance controlled endometrial ablation: long-term follow-up results. J Minim Invasive Gynecol. 2007 Jan-Feb;14(1):85-90.
  • Baskett TFClough H, Scott TA. NovaSure bipolar radiofrequency endometrial ablation: report of 200 cases. J Obstet Gynaecol Can. 2005 May;27(5):473-6.
  • Clark TJ, Samuels N, Malick S, Middleton L, Daniels J, Gupta J. Bipolar Radiofrequency Compared With Thermal Balloon Endometrial Ablation in the Office: A Randomized Controlled Trial. Obstet Gynecol. 2011 May;117(5):1228.
  • Abbott J, Hawe J, Hunter D, Garry R. A double-blind randomized trial comparing the Cavaterm and the NovaSure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertil Steril. 2003 Jul;80(1):203-8.
  • Bongers MY, Bourdrez P, Mol BW, Heintz AP, Brölmann HA. Randomised controlled trial of bipolar radio-frequency endometrial ablation and balloon endometrial ablation. BJOG. 2004 Oct;111(10):1095-102.
  • Penninx JP, Mol BW, Engels R, van Rumste MM, Kleijn C, Koks CA, Kruitwagen RFBongers MY. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2010 Oct;116(4):819-26. doi: 10.1097/AOG.0b013e3181f2e3e3.
  • Athanatos D, Pados G, Venetis CA, Stamatopoulos P, Rousso D, Tsolakidis D, Stamatopoulos CP, Tarlatzis BC. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double-blind, randomized controlled trial. Clin Exp Obstet Gynecol. 2015;42(3):347-51.